Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The aim of the study is to identify which medication (haloperidol or olanzapine) is most effective in treating nausea and abdominal pain associated with cannabinoid hyperemesis using a 10-point visual analog scale with intervals of 0.5.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:
• subjects must meet ONE of the below criteria AND are a near-daily to daily user of cannabis by inhalation for greater than or equal to 6 months.
‣ Have documented previous diagnosis of cannabinoid hyperemesis, or
⁃ Report (or on chart review) greater than or equal to 3 episodes of emesis in a cyclic pattern separated by greater than 1 month during the preceding 2 years, or
⁃ The provider suspects cannabinoid hyperemesis as the primary or equally likely primary diagnosis.
Locations
United States
Ohio
Mercy Saint Vincent Medical Center
RECRUITING
Toledo
Contact Information
Primary
Joseph Jabour, DO FACEP
jabourj1@gmail.com
3303476487
Backup
Amanda Gutek
agutek@mercy.com
Time Frame
Start Date: 2025-11-06
Estimated Completion Date: 2026-11
Participants
Target number of participants: 114
Treatments
Active_comparator: Haloperidol arm
haloperidol
Active_comparator: Olanzapine arm
olanzapine
Related Therapeutic Areas
Sponsors
Leads: Mercy Bon Secours Saint Vincent Medical Center